{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:18:42Z","timestamp":1782310722770,"version":"3.54.5"},"reference-count":40,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3,1]]},"abstract":"<jats:p>OBJECTIVE. Our goal was to report our institutional experience with recombinant factor VIIa for the treatment and\/or prevention of bleeding in nonhemophiliac children.<\/jats:p>\n               <jats:p>METHODS. This was a retrospective case series in a tertiary pediatric referral hospital.<\/jats:p>\n               <jats:p>RESULTS. During 1999\u20132006, 135 patients received recombinant factor VIIa for off-label use. The median number of doses was 2; the median dose was 88 \u03bcg\/kg. The most common diagnoses among patients receiving recombinant factor VIIa were disseminated intravascular coagulation\/sepsis (28), surgical bleeding (19), procedural prophylaxis (16), and trauma (15). The median volume of blood products administered 24 hours before recombinant factor VIIa treatment was 29.7 vs 11.7 mL\/kg 24 hours after treatment. Only 1 high-risk patient had significant bleeding after receiving prophylactic recombinant factor VIIa before an invasive procedure. Nonsurvivors had significantly increased incidence of multiple organ dysfunction syndrome (75%) compared with survivors (23%). The largest group of patients (n = 28) received recombinant factor VIIa for bleeding and\/or coagulopathy because of disseminated intravascular coagulation; the mortality in this group was 26 (93%) of 28. Eleven patients received multiple doses of recombinant factor VIIa to treat bleeding complications after hematopoietic stem cell transplant, without improvement in blood use. Mortality in medical patients was 58% vs 16% in surgical patients. Three patients had significant thrombotic adverse events after receiving recombinant factor VIIa, resulting in 2 deaths and 1 leg amputation.<\/jats:p>\n               <jats:p>CONCLUSIONS. Off-label use of recombinant factor VIIa significantly decreases blood-product administration; surgical patients had control of life-threatening bleeding with low associated mortality. Prophylactic recombinant factor VIIa may be effective in preventing bleeding if given before invasive procedures in children at high risk. Prolonged use of recombinant factor VIIa for bleeding complications after hematopoietic stem cell transplant is not effective in preventing packed red blood cell transfusion. Presence of disseminated intravascular coagulation and mulitorgan dysfunction syndrome may help predict futility of recombinant factor VIIa treatment. Off-label use of recombinant factor VIIa is associated with thromboembolic events in children.<\/jats:p>","DOI":"10.1542\/peds.2008-1685","type":"journal-article","created":{"date-parts":[[2009,3,2]],"date-time":"2009-03-02T12:49:02Z","timestamp":1235998142000},"page":"1066-1072","source":"Crossref","is-referenced-by-count":38,"title":["Pediatric Off-label Use of Recombinant Factor VIIa"],"prefix":"10.1542","volume":"123","author":[{"given":"Jeffrey A.","family":"Alten","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Benner","sequence":"additional","affiliation":[{"name":"McWhorter School of Pharmacy, Samford University, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Green","sequence":"additional","affiliation":[{"name":"McWhorter School of Pharmacy, Samford University, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Toole","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Tofil","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Winkler","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,3,1]]},"reference":[{"key":"2021120902484537700_R1","doi-asserted-by":"crossref","unstructured":"Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol.\u20082006;124(4):747\u2013757","DOI":"10.1016\/j.jbiotec.2006.03.042"},{"key":"2021120902484537700_R2","doi-asserted-by":"crossref","unstructured":"Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injures trauma patients: two randomized, placebo-controlled, double-blind clinical trials. J Trauma.\u20082005;59(1):8\u201315","DOI":"10.1097\/01.TA.0000171453.37949.B7"},{"key":"2021120902484537700_R3","doi-asserted-by":"crossref","unstructured":"Rizoli S, Nascimento B, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma.\u20082006;61(6):1419\u20131425","DOI":"10.1097\/01.ta.0000243045.56579.74"},{"key":"2021120902484537700_R4","doi-asserted-by":"crossref","unstructured":"Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg.\u20082007;83(2):707\u2013714","DOI":"10.1016\/j.athoracsur.2006.10.033"},{"key":"2021120902484537700_R5","doi-asserted-by":"crossref","unstructured":"Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double blind trial. Gastroenterology.\u20082004;127(4):1123\u20131130","DOI":"10.1053\/j.gastro.2004.07.015"},{"key":"2021120902484537700_R6","doi-asserted-by":"crossref","unstructured":"Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med.\u20082005;352(8):777\u2013785","DOI":"10.1056\/NEJMoa042991"},{"key":"2021120902484537700_R7","doi-asserted-by":"crossref","unstructured":"Friederich PW, Henry CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet.\u20082003;361(9353):210\u2013205","DOI":"10.1016\/S0140-6736(03)12268-4"},{"key":"2021120902484537700_R8","doi-asserted-by":"crossref","unstructured":"Voils S. Pharmacologic interventions for the management of critical bleeding. Pharmacology.\u20082007;27:69S\u201384S","DOI":"10.1592\/phco.27.9part2.69S"},{"key":"2021120902484537700_R9","doi-asserted-by":"crossref","unstructured":"MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion.\u20082005;45(9):1434\u20131442","DOI":"10.1111\/j.1537-2995.2005.00548.x"},{"key":"2021120902484537700_R10","doi-asserted-by":"crossref","unstructured":"O'Connell K, Wood J, Wise R, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA.\u20082006;3:293\u2013298","DOI":"10.1001\/jama.295.3.293"},{"key":"2021120902484537700_R11","doi-asserted-by":"crossref","unstructured":"Pollack MM, Ruttiman UE, Getson PR. The Pediatric risk of mortality (PRISM) score. Crit Care Med.\u20081988;16(11):1110\u20131116","DOI":"10.1097\/00003246-198811000-00006"},{"key":"2021120902484537700_R12","doi-asserted-by":"crossref","unstructured":"Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med.\u20082005;6(1):2\u20138","DOI":"10.1097\/01.PCC.0000149131.72248.E6"},{"key":"2021120902484537700_R13","doi-asserted-by":"crossref","unstructured":"Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost.\u20082004;92(4):738\u2013746","DOI":"10.1160\/TH04-03-0163"},{"key":"2021120902484537700_R14","doi-asserted-by":"crossref","unstructured":"Reiter PD, Valuck RJ, Taylor RS. Evaluation of off-label recombinant activated factor VII for multiple indications in children. Clin Appl Thromb Hemost.\u20082007;13(3):233\u2013240","DOI":"10.1177\/1076029607302402"},{"key":"2021120902484537700_R15","doi-asserted-by":"crossref","unstructured":"Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg.\u20082007;84(1):161\u2013169","DOI":"10.1016\/j.athoracsur.2007.02.051"},{"key":"2021120902484537700_R16","doi-asserted-by":"crossref","unstructured":"Pettersson M, Fischler B, Petrini P, et al. Recombinant FVIIa in children with liver disease. Thromb Res.\u20082005;116(3):185\u2013197","DOI":"10.1016\/j.thromres.2004.11.020"},{"key":"2021120902484537700_R17","doi-asserted-by":"crossref","unstructured":"Brady K, Easley B, Tobias J. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Pediatr Anaesth.\u20082006;16(10):1042\u20131046","DOI":"10.1111\/j.1460-9592.2006.02039.x"},{"key":"2021120902484537700_R18","doi-asserted-by":"crossref","unstructured":"Tobias J, Groeper K, Berkenbosch J. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J.\u20082003;96(1):12\u201316","DOI":"10.1097\/01.SMJ.0000047629.79538.82"},{"key":"2021120902484537700_R19","doi-asserted-by":"crossref","unstructured":"Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Pediatr Anaesth.\u20082005;15(3):235\u2013240","DOI":"10.1111\/j.1460-9592.2005.01429.x"},{"key":"2021120902484537700_R20","doi-asserted-by":"crossref","unstructured":"Das P, Carcao M, Hitzler J. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. Pediatr Blood Cancer.\u20082006;47(2):206\u2013209","DOI":"10.1002\/pbc.20467"},{"key":"2021120902484537700_R21","doi-asserted-by":"crossref","unstructured":"Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost.\u20082005;3(4):640\u2013648","DOI":"10.1111\/j.1538-7836.2005.01203.x"},{"key":"2021120902484537700_R22","doi-asserted-by":"crossref","unstructured":"Vincent JL, Rossaint R, Ozier Y, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care.\u20082006;10(4):R120","DOI":"10.1186\/cc5026"},{"key":"2021120902484537700_R23","doi-asserted-by":"crossref","unstructured":"Levi M, Peters M, Buller HR. Efficacy and safety of recombinant actor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med.\u20082005;33(4):883\u2013890","DOI":"10.1097\/01.CCM.0000159087.85970.38"},{"key":"2021120902484537700_R24","unstructured":"Stein DM, Dutton RP, O'Connor J, et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma.\u20082005;59(3):609\u2013615"},{"key":"2021120902484537700_R25","doi-asserted-by":"crossref","unstructured":"Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med.\u20082006;355(13):1303\u20131305","DOI":"10.1056\/NEJMp068178"},{"key":"2021120902484537700_R26","doi-asserted-by":"crossref","unstructured":"Levi M. Disseminated intravascular coagulation. Crit Care Med.\u20082007;35(9):2191\u20132195","DOI":"10.1097\/01.CCM.0000281468.94108.4B"},{"key":"2021120902484537700_R27","doi-asserted-by":"crossref","unstructured":"Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis.\u20082005;16(8):549\u2013555","DOI":"10.1097\/01.mbc.0000186837.78432.2f"},{"key":"2021120902484537700_R28","doi-asserted-by":"crossref","unstructured":"Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa\/NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang.\u20082006;90(1):45\u201352","DOI":"10.1111\/j.1423-0410.2005.00711.x"},{"key":"2021120902484537700_R29","doi-asserted-by":"crossref","unstructured":"Bowles KM, Park GR, Callaghan CJ, et al. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. Br J Anaesth.\u20082006;97(4)4:476\u2013481","DOI":"10.1093\/bja\/ael205"},{"key":"2021120902484537700_R30","doi-asserted-by":"crossref","unstructured":"Clark AD, Gordon WC, Walker ID, et al. \u201cLast-ditch\u201d use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang.\u20082004;86(2):120\u2013124","DOI":"10.1111\/j.0042-9007.2004.00393.x"},{"key":"2021120902484537700_R31","doi-asserted-by":"crossref","unstructured":"Johnson SJ, Ross MB, Moores KG. Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. Am J Health Syst Pharm.\u20082007;64(17):1808\u20131812","DOI":"10.2146\/ajhp060398"},{"key":"2021120902484537700_R32","doi-asserted-by":"crossref","unstructured":"Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost.\u20082005;3(9):1935\u20131944","DOI":"10.1111\/j.1538-7836.2005.01523.x"},{"key":"2021120902484537700_R33","doi-asserted-by":"crossref","unstructured":"Ghorashian S, Hunt B. \u201cOff-license\u201d use of recombinant activated factor VII. Blood Rev.\u20082004;18(4):245\u2013259","DOI":"10.1016\/j.blre.2003.12.003"},{"key":"2021120902484537700_R34","doi-asserted-by":"crossref","unstructured":"Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant Factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg.\u20082005;80(1):66\u201371","DOI":"10.1016\/j.athoracsur.2005.02.044"},{"key":"2021120902484537700_R35","doi-asserted-by":"crossref","unstructured":"Levy JH, Fingerhut A, Brott T, et al. Recombinant factorVIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion.\u20082006;46(6):919\u2013933","DOI":"10.1111\/j.1537-2995.2006.00824.x"},{"key":"2021120902484537700_R36","doi-asserted-by":"crossref","unstructured":"Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma.\u20082007;62(3):564\u2013569","DOI":"10.1097\/TA.0b013e318031afc2"},{"key":"2021120902484537700_R37","doi-asserted-by":"crossref","unstructured":"Khan ZH, Soltani AE, Rahmani P. Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation. J Anesth.\u20082007;21(2):258\u2013260","DOI":"10.1007\/s00540-006-0481-y"},{"key":"2021120902484537700_R38","doi-asserted-by":"crossref","unstructured":"Libman RB, Lungu C, Kwiatkowski T. Multiple ischemic strokes associated with use of recombinant activated factor VII. Arch Neurol.\u20082007;64(6):879\u2013881","DOI":"10.1001\/archneur.64.6.879"},{"key":"2021120902484537700_R39","doi-asserted-by":"crossref","unstructured":"Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis.\u20082006;17(5):389\u2013395","DOI":"10.1097\/01.mbc.0000233369.03358.c1"},{"key":"2021120902484537700_R40","doi-asserted-by":"crossref","unstructured":"Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med.\u20082006;7(1):34\u201339","DOI":"10.1097\/01.PCC.0000185491.17584.4B"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/3\/1066\/1068093\/zpe00309001066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/3\/1066\/1068093\/zpe00309001066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T15:49:53Z","timestamp":1639064993000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/3\/1066\/71693\/Pediatric-Off-label-Use-of-Recombinant-Factor-VIIa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,3,1]]},"published-print":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-1685","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,1]]}}}